Summary by Moomoo AI
On June 28, 2024, Keji Pharmaceutical Industry -B (02171.HK) submitted the disclosure report for the following day, disclosing the changes in its issued shares or treasury shares. The report shows that the number of shares issued by the company remained unchanged at 575,653,415 shares between June 25, 2024 and June 28, 2024. However, between May 31, 2024 and June 28, 2024, the company conducted multiple share buybacks, totaling 4,135,500 shares, accounting for 0.7184% of the issued shares. The last buyback occurred on June 28, 2024, when 150,000 shares were repurchased at a purchase price ranging from HKD 4.74 to HKD 4.81, with a total payment of HKD 719,950. These shares are intended to be cancelled. The company confirms that all share buybacks have obtained formal approval from the board of directors and comply with all applicable listing rules, laws, and other regulatory requirements. According to the rules, the company will not issue any new shares or resell or transfer any treasury shares within 30 days after the share buyback, i.e., until July 28, 2024.